Back to School 2020
Back to School 2020: The imperative of COVID-19 — biopharma’s once-in-a-generation chance for change
BioCentury calls on industry to convert its COVID response to a new era of efficient drug development and address the urgent healthcare chasms exposed by the crisis
BioCentury’s 28th Annual Back to School calls on biopharma to convert its COVID response to a new era of efficient drug development and address the urgent healthcare chasms exposed by the crisis.
2020 has handed biopharma an uncommon privilege: sitting at the eye of the storm, the industry has been tasked with stopping the COVID-19 pandemic that has brought the world to its knees.
To have the chance to heal so many people, save lives and restart economies is a responsibility not to be taken lightly.
Biopharma has leapt to the call, galvanizing a fractured landscape of companies to throw away their behavioral norms and do what the industry does best: innovate.
The innovation has stretched from new ways of working together, and with government, to expediting solutions for COVID-19 without compromising rigor.
Companies have launched master protocol trials in record time to accelerate testing of candidate therapies; shared data and used the pooled information to drive decisions; and used streamlined, uniform preclinical protocols to turn evolving biology into new candidates.
With this, 2020 has given biopharma a platform both to reconfigure how it goes about ALL drug development and reboot its relationship with society. For the first time in decades, the public is focused on biopharma for its ability to